The report is the first ESG report released by the company. The report covers 3D Medicines Inc. and its subsidiaries and covers the period from January 1 to December 31, 2022. The report highlights the company's practices and achievements in product liability, environmental protection, social welfare, and other aspects in 2022. The company was officially listed on HKEX, stock abbreviation: 3D Medicines, stock code: 01244.HK in December 2022. The company also completed important milestones in global cooperation. The company's first commercialized product, Envafolimab®, was approved for marketing in November 2021 and realized sales of RMB 567 million as of December 31, 2022.
Issuing Company 3D Medicines Inc.
Report Type Sustainability Report
Report Language EN
Report Filesize 51.17 MB
No. of Pages 52 pages
Reporting periodJanuary 1 to December 31, 2022
Report Edition1
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue
